Author

Yanfang Liu

Observed name: Y X Liu

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Shenzhen Third People’s Hospital

ORCID: 0009-0004-5562-6569

Observed ORCID: 0009-0004-5562-6569

OpenAlex ID: A5061987273

[Retracted: Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen].

2020 · X F Wang, J Yuan, et al. · PubMed · 105

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study

2025 · Ramaprasad Srinivasan, Othon Iliopoulos, et al. · The Lancet Oncology · 47

Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al. · Clinical Cancer Research · 32

Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease

2025 · W. Marston Linehan, Cathy Anne Pinto, et al. · European Urology · 12

2025 · Henry E. Wiley, Ramaprasad Srinivasan, et al. · Ophthalmology

Supplementary Table 3 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Supplementary Figure 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Supplementary Figure 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Supplementary Table 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Supplementary Table 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Supplementary Figure 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Data from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Supplementary Table 3 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Supplementary Table 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Supplementary Table 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Supplementary Figure 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Data from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

2024 · Tobias Else, Eric Jonasch, et al.

Works count: 17

Citation count: 194

H-index: 4

I10-index: 4